Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. .TMU Publications / 北醫出版品(教師升等著作 / 教學實踐 / 學位論文)
  3. .博碩士學位論文
  4. 108學年度
  5. 藉由抑制第一型特異性蛋白及其下游路徑來克服膠質母細胞瘤對於帝盟多藥物的阻抗性
 
  • Details
Options

藉由抑制第一型特異性蛋白及其下游路徑來克服膠質母細胞瘤對於帝盟多藥物的阻抗性

Other Title
Overcome temozolomide resistance in glioblastoma by inhibition of specific protein 1 and its’ downstream pathways
Type
thesis
Date Issued
2020-06-05
Author(s)
羅偉倫
Advisor
莊健盈
陳品元
Subjects
系所名稱:神經再生醫學博士學位學程
Description
學位別:博士
語文別:中文
指導教授:莊健盈
陳品元
口試委員:徐宗溢 Tsung-I Hsu;張光裕 Kwang-Yu Chang;高祖仁 Tzu-Jen Kao
電子論文連結:https://handle.ncl.edu.tw/11296/eqz5r6
URI
https://203.71.86.71/handle/123456789/61038

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback